Research article

Adenoviral vectors for highly selective gene expression in central serotonergic neurons reveal quantal characteristics of serotonin release in the rat brain
Kheira Benzekhroufa, Beihui Liu, Feige Tang, Anja G Teschemacher* and Sergey Kasparov*

Address: Department of Physiology and Pharmacology University of Bristol, BS8 1TD, UK
Email: Kheira Benzekhroufa - Kheira.Benzekhroufa@bristol.ac.uk; Beihui Liu - Bh.Liu@bristol.ac.uk; Feige Tang - feige.tang@bristol.ac.uk; Anja G Teschemacher* - Anja.Teschemacher@bristol.ac.uk; Sergey Kasparov* - sergey.kasparov@bristol.ac.uk
* Corresponding authors

Abstract

Background: 5-hydroxytryptamine (5 HT, serotonin) is one of the key neuromodulators in mammalian brain, but many fundamental properties of serotonergic neurones and 5 HT release remain unknown. The objective of this study was to generate an adenoviral vector system for selective targeting of serotonergic neurones and apply it to study quantal characteristics of 5 HT release in the rat brain.

Results: We have generated adenoviral vectors which incorporate a 3.6 kb fragment of the rat tryptophan hydroxylase-2 (TPH-2) gene which selectively (97% co-localisation with TPH-2) target raphe serotonergic neurones. In order to enhance the level of expression a two-step transcriptional amplification strategy was employed. This allowed direct visualization of serotonergic neurones by EGFP fluorescence. Using these vectors we have performed initial characterization of EGFP-expressing serotonergic neurones in rat organotypic brain slice cultures. Fluorescent serotonergic neurones were identified and studied using patch clamp and confocal Ca\(^{2+}\) imaging and had features consistent with those previously reported using post-hoc identification approaches. Fine processes of serotonergic neurones could also be visualized in un-fixed tissue and morphometric analysis suggested two putative types of axonal varicosities. We used micro-amperometry to analyse the quantal characteristics of 5 HT release and found that central 5 HT exocytosis occurs predominantly in quanta of \(\sim 28000\) molecules from varicosities and \(\sim 34000\) molecules from cell bodies. In addition, in somata, we observed a minority of large release events discharging on average \(\sim 800000\) molecules.

Conclusion: For the first time quantal release of 5 HT from somato-dendritic compartments and axonal varicosities in mammalian brain has been demonstrated directly and characterised. Release from somato-dendritic and axonal compartments might have different physiological functions. Novel vectors generated in this study open a host of new experimental opportunities and will greatly facilitate further studies of the central serotonergic system.
Background

Animal and human studies have associated the serotonergic (5 HTergic) system with diseases such as depression and anxiety [1-3], or schizophrenia [4,5]. Drugs which modulate 5 HT re-uptake are widely used for treatment of depression and the range of their clinical applications is expanding [6,7].

Surprisingly little is known about the neurobiology of central 5 HTergic neurones because these cells are intermingled with other cellular phenotypes even in nuclei where their density is highest. Hence, while numerous experimental and clinical studies point to 5 HT release and uptake as highly medically relevant processes [6,8], it has been impossible to directly study these processes at single cell level. In recent years, targeted expression of genes to selective cellular phenotypes has become a popular strategy for studies of brain function. We reasoned that a method for selective gene expression and manipulation in 5 HTergic neurones would be extremely useful for understanding the mechanisms by which 5 HT exerts its actions. Indeed, even an ability to directly visualize 5 HTergic neurones live within the highly heterogeneous cell milieu of the brain would offer a whole host of opportunities for electrophysiological, imaging, amperometry and other studies [9].

Two strategies may be used for selective targeting – germline transgenesis or viral vectors. Both approaches rely on the use of a cell-specific promoter (CSP) which is able to drive cell type-specific transgene expression. Transgenic mice have been developed where the enhancer region of the transcription factor Pet-1 was used to drive either Cre recombinase (Cre) or yellow fluorescent protein expression in 5 HTergic neurones [10,11]. Using Pet-1 for expressing Cre in mice with floxed allele of another transcription factor, Lmx1b, it is possible to selectively suppress 5 HTergic neurones in mice [12,13]. These mice models are a valuable resource suitable for some types of experiments. For a number of years several groups have been pursuing a different strategy, namely using viral vectors for gene expression in selected cellular groups in the brain [14-18]. One great advantage of viral transgenesis is that it is independent of the animal strain, for instance the same vector has been used to visualise catecholaminergic neurones in normo- and hypertensive rats [19]. Moreover, as critical sequences in promoters seem to be highly conserved, the same CSPs usually work equally well cross-species. For example, the synapsin-1 (SYN) promoter which is commonly used for viral gene expression in rodent studies was originally cloned from human DNA [16], and the human and mouse promoter sequences of glial fibrillary acidic protein are active and cell-specific in both rats and mice [18,20]. Therefore, with viral vectors, specific gene manipulation becomes possible in various normal and mutant lines of rats, mice and probably many other species. This becomes particularly relevant in research areas where rat models are of critical value, for example in anxiety-and depression-related studies [21,22]. Viral vectors are also highly versatile, easily transferable between laboratories and relatively inexpensive to produce. Finally and importantly, because the viral vectors can be applied to the postnatal tissue, it is possible to achieve much higher levels of transgene expression than with any standard germline transgenic approach without the risk of embryonic toxicity.

We set out to develop a viral vector system for selective targeting of central 5 HTergic neurones. First, we explored the regions upstream of the coding sequence for tryptophan hydroxylase-2 (TPH-2), the key enzyme in central neuronal 5 HT synthesis [23] and found 2 kb – 3.6 kb of the promoter region to confer selective expression to raphe 5 HTergic neurones [24]. Because these sequences were insufficiently powerful to drive visible expression of a fluorescent marker such as enhanced green fluorescent protein (EGFP) we potentiated CSP using a two-step transcriptional amplification (TSTA) strategy [24-27]. This strategy is based on simultaneous cell-specific expression of artificial transcriptional enhancers and their unique binding domains which are placed upstream of a weak CSP [20,27,28].

The lentiviral vector (LVV) generated in our previous study [24] will be a valuable resource, predominantly for in vivo experimentation on the 5 HTergic system. However, for many types of in vitro experiments, adenoviral vectors (AVV) are preferable since they are much more efficient in slice cultures and cheap to generate in large quantities [15]. The objective of the current study was therefore two-fold. First, building on the success of our previous work, we set out to generate a TSTA-amplified AVV system for specific targeting 5 HTergic neurones in organotypic slice cultures in vitro. Second, we applied this system to obtain the first information about the characteristics of quantal 5 HT release from 5 HTergic neurones of mammalian brain.

Results

The ability to visualize 5 HTergic neurones in living brain tissue preparations, rather than via post-hoc immunohistochemical identification or other less direct means of phenotype verification opens a wide range of opportunities for investigation of cellular physiology and signalling properties of these cells. Organotypic brain slice cultures transduced with AVV are excellent models for confocal imaging and electrophysiological experiments [15,29,30]. Previously, we have successfully used this approach for studies of GABAergic and catecholaminergic neurones in the brainstem [17,19,31].
In our recent study, we used LVV *in vivo* to determine those regions upstream of the TPH-2 coding sequence which confer 5-HTergic neurone-specific expression [24]. TSTA-amplified 3.6 kb promoter region (3.6 TPH) resulted in visible EGFP fluorescence in living 5-HTergic neurones which was nearly 100% specific in the brainstem areas tested. Due to the size of 3.6 TPH in relation to AVV capacity (<8 kb), in this study, we decided to use the two-promoter-copy strategy incorporated into two separate AVV (Figure 1 see [24]. We previously used similar two-vector approaches, e.g. [20,28] and know that transduced cells take up multiple copies of the viral genomes, which ensures that both parts of the system are in place. In the present experiments we employed AVV-G4BS-3.6TPH-EGFP and AVV-3.6TPH-GAL4|p65 to transduce brainstem slice cultures. Similar to the corresponding LVV described in [24], the dual AVV system demonstrated high specificity. 97% of EGFP-expressing neurones in slice cultures were also TPH-2-positive (estimate based on n~700 cells from 20 slice cultures from 4 separate preparations; Figure 2A–B). Fluorescence was clearly detectable after 2 – 3 days and reached an apparent plateau after 6–7 days. Several dozens of fluorescent neurones could be visualised in each healthy slice. We did not evaluate the duration of expression in this study but from our previous experience with AVV carrying CSP it is likely to last for the duration of the life of the slice culture. No EGFP fluorescence was evident in cultures transduced with AVV 3.6TPH-EGFP alone. Not only cell somata, but also numerous axons with characteristic varicosities could be visualized (Figure 2C). High power confocal stacks of images of living EGFP-expressing varicosities were collected and analyzed post-hoc. The absolute majority of living 5-HTergic varicosities (92% of 106 measured) were elongated (average aspect ratio 1.46) along the axonal axis and very small (median ~1.5 μm along the long axis; Figure 2C–D). Interestingly, there was also a distinct minority population (~10%) of larger varicosities with medial length ~4 μm (Figure 2C–D, red arrows).

To confirm that the EGFP-expressing 5-HTergic cells were healthy, whole-cell patch clamp recordings were obtained from median raphe neurones using the same approach as in our previous studies [17,19] (Figure 3). The patch pipette contained the red-shifted Ca2+ indicator Rhod-2 (Figure 3A, Additional file 1). Cells had membrane potentials in the range of -55 to -60 mV (n = 8, not corrected for the junction potential), and responded to positive current injections with barrages of action potentials. These were usually followed by long after-hyperpolarizations (Figure 3B–C), consistent with previous reports for raphe 5-HTergic neurones identified by post-hoc methods [32,33]. As expected, intracellular [Ca2+] increased when the cells

---

**Figure 1**

**Binary AVV system based on 3.6 TPH promoter and TSTA.** In this design, the first AVV utilises 3.6 TPH to express the chimeric recombinant transcriptional enhancer, GAL4|p65. The second AVV contains the actual transgene under control of the 3.6 TPH promoter but with G4BS (multimerised GAL4 binding sites) fused to its 5’ end. Binding of the enhancer to these sites strongly potentiates the expression of EGFP.
Figure 2 (see legend on next page)
Selective EGFP expression in raphe 5 HTergic neurons in organotypic slice cultures. A. Confocal images from slice cultures of the dorsal raphe after transduction with the dual AVV system (AVV-G4BS-3.6TPH-EGFP and AVV-3.6TPH-GAL4p65) and immunostained for TPH-2 (centre panels). EGFP expression (left panels) was 5 HT-selective (overlay of green and red channel – right panels) and sufficiently potent for single-cell experiments on live 5 HTergic neurons. Middle row of images in a higher power image of the upper one. Lower row of images is from a different slice, closer to the ventral edge (white dotted line). Yellow dashed line in upper raw shows approximate midline. B. Distribution of EGFP-expressing 5 HTergic neurons in a midbrain slice culture. Left panel – EGFP fluorescence, right panel – overlay of fluorescence channel on the DIC image. Yellow arrow points at the edge of the aqueduct. Cells are largely located along midline (B7/B8 groups), some more lateral cells probably come from B9 group. C. Characteristic varicosities of EGFP-expressing 5 HTergic axons. Note that varicosities are predominantly small but few of a larger type can also be observed (red arrow). D. Morphometric analysis of living 5 HTergic varicosities (n = 106) in slice cultures. The histogram shows the distribution of varicosity lengths measured along the axis of the axon. While the majority of varicosities were small (1.5–2 μm) there was a distinct sub-population of larger varicosities (median ~4 μm, red arrow). Large varicosities are rare, but could represent a specific functional phenotype.

Discussion

Most central 5 HTergic fibres originate from neurons concentrated within two clusters located close to the midline: a caudal group of the midline raphe nuclei, and a more rostral group that includes the dorsal and median raphe nuclei [34,35]. Raphe nuclei are often referred to as 5 HTergic but, in fact comprise a variety of neurochemical phenotypes. For example, both dorsal and medial raphe nuclei give rise to a glutamatergic projection towards the hippocampal formation [36] and glutamatergic neurons are intermingled with the TPH-2-positive cells which send their axons towards the same targets. Physiological roles of these parallel connections are very hard to disentangle without the help of new molecular tools such as the vectors described here. Interestingly, a generic "neuronal" promoter synapsin-1 is not suitable for targeting 5 HTergic neurons as the majority of the cells which expressed EGFP in animals injected with LVV-SYN-EGFP were non-TPH-positive [24]. Importantly, in slice cultures, vectors have access to any part of the brain tissue in contrast to in vivo micro-injections when their specificity (or lack of it) outside of the transduced area may remain unnoticed. The present results demonstrate that when AVV are applied in vitro they drive gene expression in 5 HTergic cells of various groups with very high specificity.

Because conventional AVV cannot incorporate very large transcriptional control units, we decided to place the TSTA-boosted 3.6 TPH promoter system into two separate rather than a single vector. Based on previous experience, we reasoned that the dual AVV system would function efficiently and greatly simplify vector design, leaving a generous capacity within the second vector. Here we only expressed EGFP, but in principle this system can easily accommodate larger transgenes such as bi-cistronic constructs or protein fusions.

EGFP fluorescence in present experiments was sufficient not only to visualize cell somata, but to reveal all the intricate detail of the 5 HTergic neurons’ structure including axonal varicosities. From our earlier estimates [37], we believe that many EGFP-fluorescent 5 HTergic neurons expressed ~1 μM of EGFP. This for the first time made it possible to estimate the dimensions of living varicosities without the potential artefacts of fixation. Interestingly, we observed two distinct peaks in the size distribution of varicosities: the majority with a median size of approximately 1.5 × 1 μm and a minority category which is approximately 3 times larger. Whether these two populations of varicosities are functionally different is an intriguing question which needs to be addressed in future studies.
Figure 3
Patch clamp and imaging of intracellular [Ca\textsuperscript{2+}] in 5 HTergic neurones in slice culture. 

A. Confocal image of EGFP-positive ventral raphe neurones (left panel), one of which was recorded in whole-cell configuration using a pipette solution containing Rhod-2 (centre panel; arrow indicates pipette tip).

B. Representative recording from an EGFP-positive raphe neuron. Trains of action potentials (top trace) were triggered by injections of depolarizing current (lower trace). Note the prominent after-hyperpolarizations (arrowheads).

C. Intracellular Ca\textsuperscript{2+} dynamics in a 5 HTergic neuron based on Rhod-2 fluorescence (top trace; fluorescence intensity in arbitrary units, AU). Repeated trains of action potentials (bottom trace) induced by current injections resulted in reproducible [Ca\textsuperscript{2+}] increases.
**Figure 4**

**Microamperometric analysis of 5 HT release in raphe slice culture.**

**A.** Amperometric trace from an EGFP-expressing varicosity during an active episode. Spike-like events of varying sizes are visible. Note that the noise level looks exaggerated at this time scale due to low frequency baseline variability.

**B.** Examples of amperometric spikes of various quantal sizes which were detected at 5 HTergic varicosities.

**C.** Quantal size distribution of release events at 5 HTergic varicosities and cell bodies. At somata, several large release events, outside of the main population, were observed.
Functionally, EGFP-expressing 5 HTergic neurones had features consistent with what could be anticipated based on various previous studies where post-hoc immunohistochemistry or similar approaches were used. As shown in Fig. 3, these cells have healthy resting and action potentials, generate evident after-hyperpolarisations following a train of spikes and their intracellular Ca\(^{2+}\) readily increases in response to stimulation. Thus, AVV do not have any evident detrimental effects on the transduced cells which survive in slice cultures for several weeks.

Although it was generally accepted that varicosities are the critical sites of 5 HT release, quantal characteristics of 5 HT release in the brain were previously unknown. By placing micro-amperometric electrodes on fluorescently identified cell compartments, we were able to collect initial information about this process. We found that 5 HT, alike central noradrenaline [31], is released by exocytosis not only from axonal varicosities but also from neuronal cell bodies. Because release from soma and dendrites occurs in the 5 HTergic nucleus itself while axonal release is directed towards the targets in remote brain areas it is tempting to speculate that the mechanisms which control release from these compartments could differ. Central 5 HT exocytosis occurred predominantly in quanta estimated at \(~28000\) molecules from varicosities and \(~34000\) molecules from cell bodies. In addition, in somata we observed a minority of large release events discharging on average \(~800000\) molecules. These categories of release events were comparable to the ones we previously recorded from central catecholaminergic neurones, as were their time courses [31]. However, the quantal sizes of 5 HT release were smaller than those of central catecholamine release. Also, frequencies of exocytotic events were markedly lower for 5 HT than for noradrenaline. Quantal release of 5 HT has been previously detected amperometrically from leech Retzius neurones [38,39] where two populations of release events, with average 5 HT discharge of 4700 and 80000 molecules, were postulated. Since these populations are consistent with release from the two different varieties of vesicles found in Retzius cells, namely small clear and large dense core vesicles (diameters \(~40\) nm and 90 nm based on ultrastructural data), 5 HT was suggested to be stored at intravesicular concentrations of around 0.27 M in both vesicle types [38,39].

Similar to Retzius cells, populations of small clear and large dense core vesicles (diameters \(~40\) nm and 100 nm, respectively) have been shown in central 5 HTergic and catecholaminergic neurones in the rat [40,41]. We found no convincing amperometric evidence for 5 HT release from a population of small clear vesicles. However, identification of some of the smallest release events could have been prevented by the noise limitations of our system. The main population of small release events in the rat raphe could represent release from large dense core vesicles, which should be either slightly smaller than in the leech (diameter \(~70\) nm versus \(~100\) nm), or contain a lower 5 HT concentration (0.1 M versus 0.27 M). Interestingly, the diameter of large dense core vesicles in leech somata was \(~15\)% larger than in axons [39]. If the same applies to rat central 5 HTergic neurones, this could explain why our somatic events were \(~7\)% larger than those recorded at the varicosities. For the very large 5 HT release events documented here, a morphological correlate remains to be found.

In terms of future directions, one evident path to explore is to express light-activated ion channels ChR2 and NpHR in 5 HTergic neurones [42,43] in order optically control their activity. Vectors may be constructed to express not only a fluorescent marker, but a functional gene, for example a 5 HT transporter. Although here we only describe in vivo applications of these novel AVV, they can also be used in vitro. An interesting property of AVV which we found in previous experiments with noradrenergic cells, is their ability to transduce cells via the retrograde route [9]. Because both, 5 HTergic and noradrenergic neurones have varicose un-myelinated axons, it may be possible that sub-groups of 5 HTergic neurones can be transduced by injecting AVV into their target areas. It would also be extremely interesting to see whether these AVV are suitable for targeting 5 HTergic neurones in other, non-rodent species.

Conclusion
We have generated novel TSTA-amplified AVV suitable for selective gene expression in raphe 5 HTergic neurons of rodents and obtained the first key facts about quantal release of 5 HT in the brain. Numerous avenues are now open for further inquiries into the physiology of central 5 HTergic neurones and the mechanisms of action of drugs, such as blockers of 5 HT uptake, a widely used group of anti-depressants.

Methods
Construction of TPH-2 promoter-containing viral vectors
As described previously, lead promoter fragments were PCR amplified from the sequences 5’ relative to the transcriptional initiation site of the rat brain TPH-2 gene, and inserted upstream of EGFP into a LVV shuttle plasmid [24]. These vectors also incorporated elements of TSTA. LVV were tested in vivo using microinjection into the raphe and from these experiments it was concluded that 3.6 TPH (promoter sequence starting 3.6 kb upstream of the coding region of the TPH-2 gene) drives highly specific and visible EGFP expression in 5 HTergic neurons in vivo [24]. In order to maximise space for expression cassettes, we placed the components of the TSTA system into two separate viral particles. To this end, the expression cas-
settes from the LVV shuttle plasmids pTYF-G4BS-3.6TPH-EGFP and pTYF-3.6TPH-GAL4|p65 were first transferred into the AVV shuttle plasmid, pXCX-Sw-linker, using SceI sites [44]. AVV were then produced by homologous recombination of shuttle and the helper plasmid pBHG10 in HEK293 cells. The media was collected for subsequent rounds of AVV proliferation in HEK293 cells until cytopathic effects were achieved. AVV were purified using CsCl gradient protocols [45]. Titers were established using an immunoreactivity spot assay as described previously [44].

**Viral vector transduction of dorsal raphe 5 HTergic neurons in organotypic slice cultures: Morphology, electrophysiology, electrochemistry**

Organotypic coronal slice cultures of the rat pons/midbrain containing the raphe nuclei were prepared according to previously published protocols (thickness at the time of plating 250 μm) [15]. They were transduced with a mixture of AVV-G4BS-3.6TPH-EGFP and AVV-3.6TPH-GAL4|p65 at equivalent titers of ~2 × 10^8 TU/ml (2 × 10 μl of viral stock diluted into 1 ml of plating media) at the time of plating [15]. Cultures were used between 7 and 10 days in vitro when AVV-mediated EGFP expression was fully established. Imaging experiments were carried out at 33°C in a tissue chamber mounted on a Leica-SP2 confocal microscope. Amperometric recordings were carried out under similar conditions in a chamber based on a conventional inverted fluorescent microscope (Leica).

For morphometric studies Image Pro Plus (Media Cybernetics) software was used. Individual varicosities which could be clearly identified on confocal images taken from living tissue were processed to identify varicosities and obtain their dimensions.

Whole-cell patch clamp recordings in combination with confocal measurement of intracellular [Ca^{2+}] changes were performed as described previously [17,19]. Rhod-2 was used as a Ca^{2+} indicator to avoid spectral interference with EGFP.

Microamperometric recordings with carbon fibre electrodes manufactured in house were performed at a driving voltage of +800 mV, and analyzed as previously described [19,31]. Quantal sizes (Q in Coulomb) were derived from event integrals, and converted into the number of oxidized molecules by the equation [molecules = (Q × Avogadro’s number)/n × Faraday constant], where n, the number of electrons transferred during oxidation of one transmitter molecule, is 4 for 5 HT [31,38,46].

**Immunohistochemistry**

To assess the specificity of expression, slice cultures were immunostained for TPH-2. First, cultures were fixed on their membranes in 4% formaldehyde for 20 min, removed from the membrane and incubated in 10% horse serum with 0.3% triton in PBS for 1 hour. After washing 3× with PBS, the sections were treated with 50% ethanol for 30 minutes, and washed 3× for 30 minutes in 0.1 M PBS. They were then incubated for 72 hrs at 4°C in primary mouse monoclonal anti-TPH-2 antibody (Sigma, dilution 1:500), 5% horse serum and 0.3% triton in PBS. This step was followed by an overnight incubation with secondary donkey anti-mouse Alexa594 (Invitrogen, 1:300) and 2% horse serum. To ensure complete EGFP visualization, sections were counterstained with primary rabbit anti-EGFP antibody (Invitrogen, 1:2000), followed by an overnight incubation in the secondary donkey anti-Rabbit Biotin-Sp-conjugated F(ab')2 IgG (Jackson ImmunoResearch, 1:500) and then in avidin-FITC for 4 hours. Sections were washed between incubations 3× for 30 min in PBS. Stained sections were mounted using Vectashield (Vector Labs), cover-slipped and imaged with a confocal microscope (Leica SP1) at 488 nm and 543 nm excitation for green and red channels, respectively. Channels were imaged sequentially using either 488 or 543 nm excitation to prevent "bleed" of the fluorescence between them.

**Abbreviations**

5 HT: 5-hydroxytryptamine, serotonin; AVV: adenoviral vectors; CSP: cell-specific promoter; EGFP: enhanced fluorescent protein; LVV: lentiviral vector; PBS: phosphate-buffered saline; PCR: polymerase chain reaction; THP: tryptophan hydroxylase-2.

**Authors’ contributions**

KB generated the vectors, performed amperometric recordings and immunohistochemistry. BHL advised on cloning. AGT supervised cloning, micro-amperometry, analysed the data on quantal release and edited the manuscript. FT performed patch clamp and Ca^{2+} studies. SK designed the study, analysed imaging data and wrote the manuscript.

**Additional material**

**Additional file 1**

Supplemental movie.

**Patch clamp of a 5 HT neurone in organotypic slice culture.**

Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-6750-9-23-S1.avi](http://www.biomedcentral.com/content/supplementary/1472-6750-9-23-S1.avi)

**Acknowledgements**

KB is a recipient of the Fellowship from the Algerian Government. B-HL is funded by the British Heart Foundation Programme grant (RG/07/006/23634). FT is funded by Wellcome Trust 080314/Z/06/Z. AGT was funded by the British Heart Foundation (FS/04/003)
References

1. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al.: Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.

2. Temel Y, Bootstall LJ, Boldtland A, Magill PJ, Steinbusch HW, Visser-Vandewalle V, et al.: Inhibition of 5-HT neuron activity and induction of depressive-like behavior by high-frequency stimulation of the subthalamic nucleus. PNAS 2007, 104:17087-17092.

3. Jennings KA, Loder MK, Sheward WJ, Pei Q, Deacon RM, Benson MA, et al.: Increased expression of the 5-HT transporter confers a low-anxiety phenotype linked to decreased 5-HT transmission. J Neurosci 2006, 26:8953-8964.

4. Gonzalez-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, Lopez-Garcia J, et al.: Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008, 452:93-97.

5. Stevens DL: Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother 2008, 42:1290-1297.

6. Halbreich U: Selective serotonin reuptake inhibitors and initial oral contraceptives for the treatment of PMDD: effective but not enough. CNS Spectr 2008, 13:566-572.

7. Goddard AW, Shekhar A, Whiteman AF, McDougle CJ: Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder. Drug Discov Today 2008, 13:325-332.

8. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al.: Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386-389.

9. Kasparov S, Teschemacher AG, Hwang D-Y, Kim K-S, Lonergan T, Paton JFR: Viral Vectors as Tools for Studies of Central Cardiovascular Control. Prog Brain Res 2004, 14:251-277.

10. Theruvet E, Cote F, Colin P, He Y, Lebois H, Pircicardet M, et al.: Targeting conditional gene modification into the serotonin neurons of the dorsal raphe nucleus by viral delivery of the Cre recombinase. Mol Cell Neurosci 2003, 24:139-147.

11. Scott MM, Wylie CJ, Lerch JK, Murphy R, Lobur K, Hertlize S, et al.: A genetic approach to access serotonin neurons for in vivo and in vitro studies. PNAS USA 2005, 102:16472-16477.

12. Zhao ZQ, Gao YJ, Sun YG, Zhao CS, Gereau RW, Chen ZF: Enhancing the nuclear tractus solitarii. 2001, 78-93.

13. Dai JX, Han HL, Tian M, Cao J, Xiu JB, Song NN, et al.: Expression of different cellular promoters in recombinant adenoviral vectors. Human Gene Ther 2001, 12:789-793.

14. Steakemacher AG, Stewmand JF, Kasparov S: Imaging living central neurons using viral gene transfer. Advanced Drug Delivery Reviews 2000, 42:149-163.

15. Kitchen S, Teschemacher AG, Paton JFR: Mechanism of nitric oxide action on inhibitory GABAergic signaling within the nucleus tractus solitarii. FASEB Journal 2006, 20:1537-1539.

16. de Leeuw B, Su M, ter Horst M, Iwata S, Rodijk M, Hoenen RC, et al.: In vivo glutamatergic synaptic transmission with a glial fibrillary acidic protein promoter containing multiple enhancer elements. J Neurosci Res 2006, 83:744-753.

17. Steakemacher AG, Wang S, Raizada MK, Paton JFR, Kasparov S: Area-specific differences in transmitter release in central catecholaminergic neurons of spontaneously hypertensive rats. Hypertension 2008, 52:1-8.

18. Liu BH, Paton JFR, Kasparov S: Viral vectors based on bidirectional cell-specific mammalian promoters and transcripational amplification strategy for use in vivo and in vitro. BMC Biotechnol 2005, 8:49.

19. Cools R, Roberts AC, Robbins TW: Serotoninergic regulation of emotional and behavioural control processes. Trends Cogn Sci 2008, 12:31-40.

20. Weiss JM, West CH, Emery MS, Bonsall RW, Moore JP, Boss-Wil- liams KA: Rats selectively-bred for behavior related to affective disorders: proclivity for intake of alcohol and drugs of abuse, and measures of brain monoamines. Biochem Pharmacol 2008, 75:134-159.

21. Walther DJ, Peter JJ, Bashamahak S, Hortnagl H, Voits M, Fink H, et al.: Synthesis of serotonin by a second tryptophan hydroxylation isomerase: Immunoreactive serotonin in the central nervous system. J Comp Neurol 2003, 452:1390-13945.

22. Benzekoura K, Liu BH, Teschemacher AG, Kasparov S: Targeting central serotonergic neurons with lentiviral vectors based on transcriptional amplification strategy. Gene Ther 2009 in press.

23. Netterbeck DM, Jerome V, Muller R: A strategy for enhancing the transcriptional activity of weak cell type-specific promoters. Gene Ther 1998, 5:1656-1664.

24. Iyer M, Wu L, Carey M, Wang Y, Smallwood A, Gambhir SS: Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. PNAS 2001, 98:14559-14560.

25. Liu BH, Yang Y, Paton JFR, Li F, Boulaire J, Kasparov S, et al.: GAL4-NFkb fusion protein augments transgene expression from neuronal promoters in the rat brain. Mol Ther 2006, 14:872-882.

26. Liu B, Wang S, Brenner M, Paton JF, Kasparov S: Enhancement of cell-specific transgene expression from a Tet-Off regulatory system using a transcriptional amplification strategy in the rat brain. J Gene Med 2008, 10:583-592.

27. Kasparov S, Teschemacher A, Paton JFR: Dynamic confocal imaging of acute brain slices and organotypic slice cultures using a spectral confocal microscope with single photon excitation. Exp Physiol 2002, 87:715-724.

28. Teschemacher AG, Wang S, Lonergan T, Duale H, Waki H, Paton JFR, et al.: Targeting specific neuronal populations in the brainstem using adeno- and lentiviral vectors: applications for imaging and studies of cell function. Exp Physiol 2005, 90:61-69.

29. Chiti Z, Teschemacher AG: Exocytosis of norepinephrine at axon varicosities and neuronal cell bodies in the rat brain. FASEB J 2007, 21:2540-2550.

30. Wang W, Tiwari JK, Bradley SR, Zaykin RV, Richerson GB: Acidosis-stimulated neurons of the medullary raphe are serotonergic. J Neurophysiol 2001, 85:2224-2235.

31. Yasuo-Takano J, Nakajima S, Nakajima Y: Morphological and physiological properties of serotonergic neurons in associated cultures from the postnatal rat dorsal raphe nucleus. J Neurosci Methods 2008, 167:258-267.

32. Steinbusch HW, Nieuwenhuys R: Localization of serotonin-like immunoreactivity in the central nervous system and pituitary of the rat, with particular references to the innervation of the hypothalamus. Adv Exp Med Biol 1981, 133:7-35.

33. Jacobson BL, Gannon PJ, Azmitia EC: Atlas of serotonergic cell bodies in the cat brainstem: an immunocytochemical analysis. Brain Res Bull 1984, 13:1-31.

34. Kiss J, Csaki A, Bokor H, Kocsis K, Kocsis B: Possible glutamatergi-c/aspartatergic projections to the supramammillary nucleus and their origins in the rat studied by selective [3H]Asp-aspartate labelling and immunocytochemistry. Neurosci 2002, 111:671-691.

35. Stokes CEL, Murphy D, Paton JFR, Kasparov S: Dynamics of a transgene expression in acute rat brain slices transected with adenoviral vectors. Exp Physiol 2003, 88:459-466.

36. Bruns D, Jahn R: Real-time measurement of transmitter release from single synaptic vesicles. Nature 1995, 377:62-65.

37. Bruns D, Riedel D, Klingauf J, Jahn R: Quantal release of seroton- on. Neuron 2000, 28:205-220.

38. Beaudet A, Descarries L: The fine structure of central serotonin nerve terminals. Brain Res 1981, 200:193-203.

39. Bloom FE, Aghajanian GK: An electron microscopic analysis of large granular synaptic vesicles of the brain in relation to monoamine content. J Pharmacol Exp Ther 1968, 159:261-273.

40. Nagel G, Szellas T, Huhn W, Kateriya S, Adeishvili N, Berthold P, et al.: Channelrhodopsin-2, a directly light-gated cation-selective membrane channel. PNAS 2003, 100:13940-13945.

41. Zhang F, Wang LP, Brauner M, Liejend LF, Kay K, Watzke N, et al.: Multimodal fast optical interrogation of neural circuitry. Nature 2007, 446:633-639.
44. Duale H, Kasparov S, Paxon JFR, Teschemacher AG: Differences in transductional tropism of adenoviral and lentiviral vectors in the rat brainstem. Exp Physiol 2005, 90:71-78.
45. Graham FL, Prevec L: Methods for construction of adenovirus vectors. Mol Biotechnol 1995, 3:207-220.
46. Wightman RM, Jankowski JA, Kennedy RT, Kawagoe KT, Schroder TJ, Leszczyszn DJ, et al.: Temporally resolved catecholamine spikes correspond to single vesicle release from individual chromaffin cells. PNAS 1991, 88:10754-10758.